165 related articles for article (PubMed ID: 18990560)
1. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
Loi S
Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
[TBL] [Abstract][Full Text] [Related]
2. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
[TBL] [Abstract][Full Text] [Related]
3. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
4. The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response.
Loi S; Piccart M; Sotiriou C
Crit Rev Oncol Hematol; 2007 Mar; 61(3):187-94. PubMed ID: 17088071
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications.
Badve S; Nakshatri H
J Clin Pathol; 2009 Jan; 62(1):6-12. PubMed ID: 18794199
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles of the oestrogen receptor in breast cancer.
Kok M; Linn SC
Neth J Med; 2010 Oct; 68(10):291-302. PubMed ID: 21071774
[TBL] [Abstract][Full Text] [Related]
8. [Gene expression profiling of ER+ breast cancers: to discriminate the poor prognosis tumors or to define the most suitable treatment?].
Chanrion M; Darbon JM
Bull Cancer; 2008 May; 95(5):513-8. PubMed ID: 18541515
[TBL] [Abstract][Full Text] [Related]
9. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Loi S; Haibe-Kains B; Desmedt C; Lallemand F; Tutt AM; Gillet C; Ellis P; Harris A; Bergh J; Foekens JA; Klijn JG; Larsimont D; Buyse M; Bontempi G; Delorenzi M; Piccart MJ; Sotiriou C
J Clin Oncol; 2007 Apr; 25(10):1239-46. PubMed ID: 17401012
[TBL] [Abstract][Full Text] [Related]
10. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
11. Prediction of hormone sensitivity for breast cancers.
Miyoshi Y; Murase K; Saito M; Oh K
Breast Cancer; 2010 Apr; 17(2):86-91. PubMed ID: 19806427
[TBL] [Abstract][Full Text] [Related]
12. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
[TBL] [Abstract][Full Text] [Related]
13. A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.
Habashy HO; Powe DG; Abdel-Fatah TM; Gee JM; Nicholson RI; Green AR; Rakha EA; Ellis IO
Histopathology; 2012 May; 60(6):854-63. PubMed ID: 21906125
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
Linn SC; Van 't Veer LJ
Eur J Cancer; 2009 Sep; 45 Suppl 1():11-26. PubMed ID: 19775601
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
17. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
Sgroi DC; Haber DA; Ryan PD; Ma XJ; Erlander MG
Cancer Cell; 2004 Nov; 6(5):445. PubMed ID: 15542428
[No Abstract] [Full Text] [Related]
18. Molecular classification of estrogen receptor-positive/luminal breast cancers.
Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
[TBL] [Abstract][Full Text] [Related]
19. GATA-3 as a marker of hormone response in breast cancer.
Fang SH; Chen Y; Weigel RJ
J Surg Res; 2009 Dec; 157(2):290-5. PubMed ID: 19059610
[TBL] [Abstract][Full Text] [Related]
20. What clinicians need to know about antioestrogen resistance in breast cancer therapy.
Milano A; Dal Lago L; Sotiriou C; Piccart M; Cardoso F
Eur J Cancer; 2006 Nov; 42(16):2692-705. PubMed ID: 16963260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
